LONDON (dpa-AFX) - GlaxoSmithKline plc, (GSK, GSK.L), a research-based pharmaceutical and healthcare company and Theravance, Inc.(THRX), a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies, Monday announced the submission of a regulatory application to the Japanese Ministry of Health, Labour and Welfare or MHLW, for the investigational once-daily long-acting muscarinic antagonist or LAMA/ a long-acting beta2 agonist or LABA combination medicine, UMEC/VI for patients with chronic obstructive pulmonary disease or COPD.
The companies also announced the submission of a regulatory application for UMEC/VI for patients with COPD in the United States on December 18, 2012 and in Europe on January 9, 2013.
A New Drug Application for UMEC/VI in 62.5/25mcg and 125/25mcg doses, with the proposed proprietary name ANORO ELLIPTA, has been submitted to the Japanese MHLW as a maintenance bronchodilator treatment to relieve symptoms of obstructive airway disorder due to COPD (chronic bronchitis and emphysema).
UMEC/VI is a combination of two investigational bronchodilator molecules - umeclidinium bromide, LAMA and vilanterol, LABA administered using the ELLIPTA inhaler.
GSK announced that it intends to commence global regulatory submissions for UMEC monotherapy later this year.
Copyright(c) 2013 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX